Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials - PubMed
3 days ago
- #biomarkers
- #clinical trials
- #idiopathic pulmonary fibrosis
- Study investigates prognostic biomarkers for idiopathic pulmonary fibrosis (IPF) using data from the ISABELA trials, the largest IPF cohort to date.
- Key findings include higher baseline levels of matrix metalloproteinase-7 (MMP-7) in patients with ≥10% annual decline in forced vital capacity (FVC).
- Patients with baseline MMP-7 ≥5.2 μg·L-1 and/or CCL18 ≥75.2 μg·L-1 had significantly increased mortality risk.
- Machine learning identified changes in CCL18 by week 26 as a predictor of disease progression.
- The MUC5B (rs35705950_T) genotype did not predict mortality or disease progression.
- Combination of high baseline MMP-7 and CCL18 levels, along with longitudinal CCL18 changes, may enhance risk stratification in IPF patients.